Care Alliance Health Center

carealliance.org

Care Alliance is a Level 3 NCQA Patient-Centered Medical Home and non-profit, Federally Qualified Health Center that provides health care to low-income individuals and families living in Cleveland. Care Alliance was founded in 1985 as one of the original 19 Robert Wood Johnson Foundation/Pew Health Care for the Homeless pilot projects. Our mission is to provide high-quality, comprehensive medical and dental care, patient advocacy and related services to people who need them most, regardless of their ability to pay. Each year Care Alliance serves over 10,000 Clevelanders. In April 2015, Care Alliance opened a state-of-the-art clinic in Cleveland’s Central Neighborhood with the capacity to care for 12,000 underserved individuals and deliver $6.4 million in annual community benefit.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Diagnostics

AVID BIOSERVICES UNVEILS COMPLETED MAMMALIAN CELL FACILITIES EXPANSION PROVIDING SIGNIFICANTLY INCREASED CAPACITY FOR EXISTING AND FUTURE CUSTOMERS

Globenewswire | April 10, 2023

news image

Avid Bioservices, Inc. a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the completion of two expansions within the company’s mammalian cell facilities. The company expects that the first customer for the newly expanded CGMP mammalian cell suites will begin manufacture this month. To celebrate the launch of...

Read More

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

news image

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More

Industry Outlook

OPENTRONS PARTNERS WITH ZYMO RESEARCH TO AUTOMATE KEY MICROBIOME CHEMISTRIES ON THE OPENTRONS FLEX™

PRNewswire | June 16, 2023

news image

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex. Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently fa...

Read More

Research, Diagnostics

XILIO THERAPEUTICS RELEASES PRELIMINARY RESULTS OF XTX101 PHASE 1 TRIAL

Globenewswire | May 26, 2023

news image

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors. “We are encouraged by the preliminary data from the Phase 1 trial for XTX101 showing evidence of tumor-selective ...

Read More
news image

Industrial Impact, Diagnostics

AVID BIOSERVICES UNVEILS COMPLETED MAMMALIAN CELL FACILITIES EXPANSION PROVIDING SIGNIFICANTLY INCREASED CAPACITY FOR EXISTING AND FUTURE CUSTOMERS

Globenewswire | April 10, 2023

Avid Bioservices, Inc. a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the completion of two expansions within the company’s mammalian cell facilities. The company expects that the first customer for the newly expanded CGMP mammalian cell suites will begin manufacture this month. To celebrate the launch of...

Read More
news image

AI

VIVA BIOTECH AND BIOMAP HAVE SIGNED A STRATEGIC COLLABORATION AGREEMENT TO ACCELERATE EARLY DRUG DISCOVERY USING AI TECHNOLOGY

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Read More
news image

Industry Outlook

OPENTRONS PARTNERS WITH ZYMO RESEARCH TO AUTOMATE KEY MICROBIOME CHEMISTRIES ON THE OPENTRONS FLEX™

PRNewswire | June 16, 2023

Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics and Zymo Research Corp, a life science reagent company, are collaborating to transform microbiome and metagenome analysis by fully automating comprehensive, end-to-end workflows from sample collection through library preparation on the Opentrons Flex. Traditional methods of microbiome analysis have provided valuable insights across various applications; however, this approach frequently fa...

Read More
news image

Research, Diagnostics

XILIO THERAPEUTICS RELEASES PRELIMINARY RESULTS OF XTX101 PHASE 1 TRIAL

Globenewswire | May 26, 2023

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced preliminary data from its Phase 1 clinical trial evaluating XTX101, an investigational tumor-activated, Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors. “We are encouraged by the preliminary data from the Phase 1 trial for XTX101 showing evidence of tumor-selective ...

Read More